Page 1 | Search Results | Blood | American Society of Hematology

1-9 of 9

Sort by

Sort Order Select

Journal Articles

Prevention of CMV/EBV Reactivation By Double-Specific T Cells in Patients after Allogeneic Stem Cell Transplantation: Results from the Randomized Phase I/IIa Multivir-01 Study

Blood (2023) 142 (Supplement 1): 6849.

https://doi.org/10.1182/blood-2023-178273

Published: 2023

Journal Articles

CNS Irradiation in Adult De Novo B-Precursor ALL / Lbl: Results of the Randomized GMALL T rial 08/2013 Indicate Potential Antileukemic Efficacy

Blood (2023) 142 (Supplement 1): 828.

https://doi.org/10.1182/blood-2023-179442

Published: 2023

Journal Articles

Inotuzumab Ozogamicin Induction Followed By Standard Chemotherapy Yields High Remission Rates and Promising Survival in Older (>55 Years) Patients with De Novo B-Lymphoblastic Leukemia (GMALL-Initial1 Trial)

Blood (2022) 140 (Supplement 1): 510–512.

https://doi.org/10.1182/blood-2022-162235

Published: 2022

Journal Articles

Outcome of 841 Older Patients (>55 yrs) with Newly Diagnosed Ph/BCR-ABL Negative ALL Prospectively Treated According to Pediatric-Based, Age-Adapted GMALL Protocols

Blood (2022) 140 (Supplement 1): 121–123.

https://doi.org/10.1182/blood-2022-158934

Published: 2022

Journal Articles

Final Induction Therapy Results of an Open Label Phase II Study Using Inotuzumab Ozogamicin for Induction Therapy, Followed By a Conventional Chemotherapy Based Consolidation and Maintenance Therapy in Patients Aged 56 Years and Older with Acute B-Lymphoblastic Leukemia (INITIAL-1 trial)

Blood (2021) 138 (Supplement 1): 2300.

https://doi.org/10.1182/blood-2021-145553

Published: 2021

Journal Articles

Comorbidities Are Frequent in Older Patients with De Novo Acute Lymphoblastic Leukemia (ALL) and Correlate with Induction Mortality: Analysis of More Than 1200 Patients from GMALL Data Bases

Blood (2018) 132 (Supplement 1): 660.

https://doi.org/10.1182/blood-2018-99-111954

Published: 2018

Journal Articles

Evaluation of Minimal Residual Disease (MRD) and MRD-Based Treatment Decisions in Ph/BCR-ABL Negative Adult Acute Lymphoblastic Leukemia (ALL): Experience from the German Multicenter Study Group for Adult ALL (GMALL)

Nicola Goekbuget, MD, Monika Brüggemann, Joachim Beck, MD, Christoph Faul, MD, Christian Koenecke, MD, Heinz A. Horst, MD PhD, Mustafa Kondakci, MD, Doris M. Kraemer, MD, PhD, Christoph Lutz, MD, Bernd Spriewald, MD, Michael Starck, MD, Christoph Rollig, MD MSC, Matthias Stelljes, MD, Andreas Viardot, MD, Ralph Wäsch, Knut Wendelin, MD, Hubert Serve, Michael Kneba, MD, Dieter Hoelzer, MD PhD

Blood (2017) 130 (Supplement 1): 139.

https://doi.org/10.1182/blood.V130.Suppl_1.139.139

Published: 2017

Journal Articles

Adoptive Transfer of Purified Donor-B-Lymphocytes after Allogeneic Stem Cell Transplantation: Results from a Phase I/IIa Clinical Trial

Julia Winkler, MD, Hannes Tittlbach, Wolf Roesler, MD, Julian Strobel, MD, Roland Zimmermann, MD, Stefanie Maas, MD, Bernd Spriewald, MD, Daniel Wolff, MD, Roland Repp, MD, Lambros Kordelas, MD, Michael Mach, PhD, Andreas Mackensen, MD, Thomas H. Winkler, PhD

Blood (2016) 128 (22): 502.

https://doi.org/10.1182/blood.V128.22.502.502

Published: 2016

Journal Articles

the IKZF1-IRF4 Axis Regulates Macrophage Polarization and Macrophage-Mediated Anti-Tumor Immunity

Heiko Bruns, PhD, Dimitrios Mougiakakos, Christian Bach, Martin Böttcher, Joerg Thomas Bittenbring, MD, Maike Büttner, Kolja Gelse, Michael Rehli, Julia Wimmer, Fabian Beier, MD, Deniz Gezer, Jan Krönke, MD, Heidi Balzer, Stephanie Moi, Bernd Spriewald, MD, Andreas Mackensen, MD, Leonhard Busch

Blood (2016) 128 (22): 2514.

https://doi.org/10.1182/blood.V128.22.2514.2514

Published: 2016

NARROW

Prevention of CMV/EBV Reactivation By Double-Specific T Cells in Patients after Allogeneic Stem Cell Transplantation: Results from the Randomized Phase I/IIa Multivir-01 Study

CNS Irradiation in Adult De Novo B-Precursor ALL / Lbl: Results of the Randomized GMALL T rial 08/2013 Indicate Potential Antileukemic Efficacy

Inotuzumab Ozogamicin Induction Followed By Standard Chemotherapy Yields High Remission Rates and Promising Survival in Older (>55 Years) Patients with De Novo B-Lymphoblastic Leukemia (GMALL-Initial1 Trial)

Outcome of 841 Older Patients (>55 yrs) with Newly Diagnosed Ph/BCR-ABL Negative ALL Prospectively Treated According to Pediatric-Based, Age-Adapted GMALL Protocols

Final Induction Therapy Results of an Open Label Phase II Study Using Inotuzumab Ozogamicin for Induction Therapy, Followed By a Conventional Chemotherapy Based Consolidation and Maintenance Therapy in Patients Aged 56 Years and Older with Acute B-Lymphoblastic Leukemia (INITIAL-1 trial)

Comorbidities Are Frequent in Older Patients with De Novo Acute Lymphoblastic Leukemia (ALL) and Correlate with Induction Mortality: Analysis of More Than 1200 Patients from GMALL Data Bases

Evaluation of Minimal Residual Disease (MRD) and MRD-Based Treatment Decisions in Ph/BCR-ABL Negative Adult Acute Lymphoblastic Leukemia (ALL): Experience from the German Multicenter Study Group for Adult ALL (GMALL)

Adoptive Transfer of Purified Donor-B-Lymphocytes after Allogeneic Stem Cell Transplantation: Results from a Phase I/IIa Clinical Trial

the IKZF1-IRF4 Axis Regulates Macrophage Polarization and Macrophage-Mediated Anti-Tumor Immunity

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only